Anti-cyclic citrullinated peptide (Anti-CCP) and anti-mutated citrullinated vimentin (Anti-MCV) relation with extra-articular manifestations in rheumatoid arthritis

We evaluated the association between anti-cyclic citrullinated peptide antibodies (anti-ccp) and anti-mutated citrullinated vimentin antibodies (anti-mcv) with the presence of extra-articular (exra) manifestations in 225 patients with rheumatoid arthritis (ra). ninety-five patients had exra and 130 had no exra. there was no association of anti-ccp and anti-mcv levels with the presence of exra as total group (p = 0.40 and p = 0.91,resp.). making an analysis of individual manifestations,rheumatoid nodules were associated with positivity for rheumatoid factor (rf); (p = 0.01),anti-ccp (p = 0.048),and anti-mcv (p = 0.02). instead,rf,anti-ccp,or anti-mcv were not associated with ss,chronic anemia,or peripheral neuropathy. levels of anti-ccp correlated with the score of the health assessment questionnaire-disability index (haq-di) (r = 0.154,p = 0.03),erythrocyte sedimentation rate (esr); (r = 0.155,p = 0.03),and rf (p = 0.254,p < 0.001),whereas anti-mcv titres only correlated with rf (r = 0.169,p = 0.02). on adjusted analysis,exra was associated with longer age (p = 0.015),longer disease duration (p = 0.007),higher das-28 score (p = 0.002),and higher haq-di score (p = 0.007),but serum levels of anti-ccp and anti-mcv were not associated. these findings show the need to strengthen the evaluation of the pathogenic mechanisms implied in each specific exra manifestation. © 2014 laura gonzalez-lopez et al.